Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -304.78% is 124% below its 5-year average of -136.09%, around the middle of its 5-year range (-816.54%–-19.89%).
As of the fiscal period ended Tuesday, June 30, 2026. 0.63% above its 12-month average of -306.72%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -304.78%.
RETURN ON EQUITY (ROE)
-304.78%
RETURN ON EQUITY (ROE) AVG TTM
-306.72%
RETURN ON EQUITY (ROE) AVG 3Y
-261.91%
RETURN ON EQUITY (ROE) AVG 5Y
-136.09%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+0.63%
CURRENT VS 3Y AVG
-16.37%
CURRENT VS 5Y AVG
-123.95%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-40.89%
median of 684 covered companies
CURRENT VS SECTOR MEDIAN
-645.37%
vs the sector median at left
Femasys Inc.
Market Cap
$6.22M
Return on Equity (ROE)
-304.78%
TTM Avg
-306.72%
3Y Avg
-261.91%
5Y Avg
-136.09%
Market Cap
$6.01M
Return on Equity (ROE)
-59.21%
TTM Avg
-23.87%
3Y Avg
-948.19%
5Y Avg
-660.49%
Market Cap
$6.45M
Return on Equity (ROE)
N/A
TTM Avg
-266.00%
3Y Avg
851.50%
5Y Avg
629.05%
Market Cap
$5.98M
Return on Equity (ROE)
-87.12%
TTM Avg
-90.45%
3Y Avg
-143.11%
5Y Avg
-272.17%
Market Cap
$5.94M
Return on Equity (ROE)
105.35%
TTM Avg
0.10%
3Y Avg
-37.77%
5Y Avg
-33.57%
Market Cap
$6.54M
Return on Equity (ROE)
-143.54%
TTM Avg
-132.34%
3Y Avg
-104.07%
5Y Avg
-91.90%
Market Cap
$5.86M
Return on Equity (ROE)
-111.42%
TTM Avg
-84.56%
3Y Avg
-107.54%
5Y Avg
-308.31%
Market Cap
$6.62M
Return on Equity (ROE)
-108.00%
TTM Avg
-445.77%
3Y Avg
-254.63%
5Y Avg
-239.85%
Market Cap
$5.79M
Return on Equity (ROE)
-34.33%
TTM Avg
-90.47%
3Y Avg
-81.08%
5Y Avg
-76.07%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Femasys Inc. (FEMY) | $6.22M | -304.78% | -306.72% | -261.91% | -136.09% |
| Scienture Holdings, Inc. (SCNX)vs › | $6.01M | -59.21% | -23.87% | -948.19% | -660.49% |
| Ensysce Biosciences, Inc. (ENSC)vs › | $6.45M | N/A | -266.00% | 851.50% | 629.05% |
| Cardio Diagnostics Holdings, Inc. (CDIO)vs › | $5.98M | -87.12% | -90.45% | -143.11% | -272.17% |
| Enlivex Therapeutics Ltd. (ENLV)vs › | $5.94M | 105.35% | 0.10% | -37.77% | -33.57% |
| Biomerica, Inc. (BMRA)vs › | $6.54M | -143.54% | -132.34% | -104.07% | -91.90% |
| Lucyd, Inc (LUCY)vs › | $5.86M | -111.42% | -84.56% | -107.54% | -308.31% |
| Enveric Biosciences, Inc. (ENVB)vs › | $6.62M | -108.00% | -445.77% | -254.63% | -239.85% |
| Sonoma Pharmaceuticals, Inc. (SNOA)vs › | $5.79M | -34.33% | -90.47% | -81.08% | -76.07% |
| enVVeno Medical Corporation (NVNO)vs › | $5.77M | -76.07% | -61.76% | -59.53% | -66.20% |
ROE
-304.8%
ROA
-100.0%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -304.78% |
| 2026-03-31 | -170.13% |
| 2025-12-31 | -317.38% |
| 2025-09-30 | -434.60% |
| 2024-12-31 | -816.54% |
| 2024-09-30 | -303.25% |
| 2024-06-30 | -148.37% |
| 2024-03-31 | -95.47% |
| 2023-12-31 | -77.63% |
| 2023-09-30 | -121.90% |
| 2023-06-30 | -91.00% |
| 2023-03-31 | -92.72% |
| 2022-12-31 | -74.75% |
| 2022-09-30 | -60.34% |
| 2022-06-30 | -48.44% |
| 2022-03-31 | -36.57% |
| 2021-12-31 | -28.63% |
| 2021-09-30 | -23.85% |
| 2021-06-30 | -19.89% |
| 2020-12-31 | -196.01% |
